Triomune approved for PEPFAR use

Keith Alcorn
Published: 22 November 2006

The US Food and Drug Administration announced last week that it has granted tentative approbal to a fixed dose triple combination of the antiretroviral drugs nevirapine, stavudine and lamivudine. The product is marketed by Cipla as Triomune, and will now be available for purchase by United States PEPFAR-funded treatment programmes worldwide (PEPFAR is the President's Emergency Plan for AIDS Relief, founded in 2003 to deliver antiretroviral treatment and HIV prevention in developing countries).

Triomune is already one of the most widely used generic antiretroviral products in developing countries because it combines three drugs recommended for first-line therapy by the World Health Organization into one tablet.

According to the Boston Globe, generic antiretroviral drugs now account for almost 70% of PEPFAR-funded HIV treatment in Haiti, Nigeria and Zambia, three of the 15 countries targeted by the programme.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.